EUVIMEDEUVIMED entdecken
Crossref

Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study

Carmelo Gurnari iD, Tiziana Ottone, Alfonso Piciocchi iD, Daniela Späth, Annika Meid, Giovanni Marsili iD, Emiliano Fabiani iD, Francesca Romano, Maria Rosaria Pascale iD, Paola Ricci iD, Patrizia Chiusolo iD, Mauro Di Ianni iD und 20 weitere

American Journal of Hematology · 01.11.2026

DOI: 10.1002/ajh.70546 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 01.11.2026. Verfasst von Carmelo Gurnari und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. Die Arbeit nennt 32 Literaturangaben. Gefördert von: European Hematology Association, Fondazione AIRC per la ricerca sul cancro ETS, Fondo Italiano per la Scienza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2022 ELN recommendations reclassified fms‐like tyrosine kinase‐3 ( FLT3 )‐ITD mutated acute myeloid leukemia (AML) as intermediate‐risk, irrespective of allelic ratio (AR), and designated capillary electrophoresis (CE) as the preferred detection method. However, CE requires substantial expertise, particularly to identify FLT3 ‐ITD microclones ( FLT3 ‐ITD m ; AR < 0.05), whose clinical significance remains uncertain. Herein, we investigated diagnostic aspects and the prognostic impact of FLT3 ‐ITD m . An initial methodological study performed on 48 FLT3 ‐ITD+ samples, with AR 0.001–6.00, showed overall concordance between CE and next‐generation sequencing (NGS) results ( p < 0.001), with only three microclones (AR: 0.002, 0.001, and 0.008) identified by CE and not by NGS. We next analyzed 658 AML patients diagnosed with a FLT3 ‐ITD+ AML ( n = 446 with AR ≥ 0.05, and n = 212 with a microclone) between 2017 and 2022. Patients with FLT3 ‐ITD m , as compared to patients with AR ≥ 0.05, were older, more often had secondary‐type AML, and displayed a higher prevalence of myelodysplasia‐related gene mutations, while NPM1 ‐mutation frequency was similar in the two groups. Complete remission rates were lower in FLT3 ‐ITD m (74%) than in patients with AR ≥ 0.05 (88%) treated with intensive chemotherapy without FLT3‐inhibitors (FLT3i). In the intensively treated subgroup, multivariate analyses demonstrated that age, NPM1 mutation, and allogeneic stem cell transplantation, rather than FLT3 ‐ITD AR, were independent predictors of disease‐free survival. At relapse, 15 of 33 (45%) evaluable patients remained FLT3 ‐ITD+, with 10 expanding the original microclone. In conclusion, FLT3 ‐ITD m are associated with older age, secondary AML, and with expansion of the FLT3 ‐ITD clone upon relapse, thereby providing a rationale for the evaluation of FLT3i in randomized clinical trials.

Schlagwörter

Stichwörter der Autor:innen

FLT3‐ITD microclonesacute myeloid leukemiaprognostic markers

Autor:innen und Institutionen

  • Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA.
  • Centro Dati, Fondazione GIMEMA Franco Mandelli, Roma, Italy.
  • Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
  • Department of Radiological and Hematological Sciences, Catholic University, Rome, Italy.
  • Hematology Unit, Department of Oncology and Hematology, Santo Spirito Hospital, Pescara, Italy.

ORCID-Profile: Carmelo Gurnari, Alfonso Piciocchi, Giovanni Marsili, Emiliano Fabiani, Maria Rosaria Pascale, Paola Ricci, Patrizia Chiusolo, Mauro Di Ianni, Marta Sobas, Joana Brioso Infante, Jacopo Nanni, Calogero Vetro, Anna Candoni, Jorge Sierra, Nicola Potter, Amanda Gilkes, Brian Huntly, Adriano Venditti, Nigel Russell, Richard Dillon, Hartmut Döhner, Konstanze Döhner, Maria Teresa Voso

Förderung

  • European Hematology Association
  • Fondazione AIRC per la ricerca sul cancro ETS
  • Fondo Italiano per la Scienza

Zitieren

APA

Gurnari, C., Ottone, T., Piciocchi, A., Späth, D., Meid, A., Marsili, G., Fabiani, E., Romano, F., Pascale, M. R., Ricci, P., Chiusolo, P., Ianni, M. D., Sobas, M., Brunetti, L., Oñate, G., Infante, J. B., Nanni, J., Vetro, C., Boada, M., …, & Voso, M. T. (2026). Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study. American Journal of Hematology. https://doi.org/10.1002/ajh.70546

Vancouver

Gurnari C, Ottone T, Piciocchi A, Späth D, Meid A, Marsili G, et al. Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study. American Journal of Hematology. 2026. doi:10.1002/ajh.70546

BibTeX
@article{Gurnari2026,
  author = {Gurnari, Carmelo and Ottone, Tiziana and Piciocchi, Alfonso and Späth, Daniela and Meid, Annika and Marsili, Giovanni and Fabiani, Emiliano and Romano, Francesca and Pascale, Maria Rosaria and Ricci, Paola and Chiusolo, Patrizia and Ianni, Mauro Di and Sobas, Marta and Brunetti, Lorenzo and Oñate, Guadalupe and Infante, Joana Brioso and Nanni, Jacopo and Vetro, Calogero and Boada, Matilde and Candoni, Anna and Sierra, Jorge and Potter, Nicola and Gilkes, Amanda and Johnson, Sean James and Thomas, Ian and Huntly, Brian and Venditti, Adriano and Russell, Nigel and Dillon, Richard and Döhner, Hartmut and Döhner, Konstanze and Voso, Maria Teresa},
  title = {Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70546}
}
Kostenlos starten →